The global endoscope reprocessing market is expected to generate USD 4,277.6 million revenue by 2030, advancing at a CAGR of 9.6% during 2022–2030. This will be on account of the supportive regulatory guidelines that promote the reprocessing of endoscopes, increasing cases of diseases for which endoscopies are required during diagnosis and treatment, and technological advances in endoscope reprocessing methods.
Additionally, ambulatory surgical centers are increasingly being preferred for getting MISs because they allow patients to be discharged on the same day. There are currently over 5,500 Medicare-certified ambulatory surgical centers in the U.S. Moreover, when compared to hospitals, ambulatory surgical centers provide lower-cost surgeries with greater scheduling flexibility. Thus, these centers generate a high demand for endoscope reprocessing services.
Due to the non-operational out-patient departments (OPDs) and diagnostic imaging centers, the use of endoscopes decreased during the lockdowns imposed to lower the COVID-19 spread rate. In such a scenario, the demand for reprocessing services also witnessed a negative impact till the second quarter of 2020. But, after the lockdown was lifted, the demand for endoscope repair services started growing.
The demand for automated endoscope reprocessors (AERs) is expected to show the highest CAGR, of around 11%, in the forecast period. AERs are innovative devices used in healthcare settings to reprocess endoscopes and their accessories, to decontaminate them. They are Class II devices that have been cleared through the 510(k) premarket notification pathway. By exposing the exterior surfaces and interior channels of reusable endoscopes to chemical solutions, AERs are designed to kill microorganisms.
The adoption of AERs is expected to rise in the coming years owing to the increase in the count of endoscopy procedures all over the world and the necessity to replace the manual cleaning process, thereby driving the market growth. Additionally, the rising number of endoscopy procedures and the increasing utilization of advanced, automated machines in various developing nations are augmenting the demand for AERs.
The APAC region is witnessing rapid growth owing to the rise in the chronic disease prevalence, healthcare expenditure, and rate of technological advancements. Further, the increasing prevalence of HAIs contributes to the extensive usage of disinfection systems in healthcare settings. Moreover, due to the ongoing technological advancements and improving healthcare infrastructure, the market in APAC is expected to hold a significant share in the revenue generation for the providers of endoscope reprocessing systems and services. In addition, the rise in the awareness of novel endoscopy devices and the surge in the patient preference for minimally invasive procedures propel the growth.
Colon cancer, GERD, inflammatory bowel disease (IBD), and non-alcoholic fatty liver disease are considered important emerging diseases in the APAC region. The incidence rate of colon cancer is the highest among all GI cancers in the region, even higher than that of gastric cancer. In 2020, colon and stomach cancers were the third- and fourth-biggest causes of new cancer cases in the region, accounting for more than 1.93 million (10.8%) and 1.09 million (10.6%) cases, respectively.
GERD is another highly prevalent disease in APAC, with its prevalence and that of reflux esophagitis reportedly increasing. The rising prevalence of such diseases increases the number of endoscopy procedures in the region, in turn, driving the focus on the reprocessing of endoscopes.
The major players operating in the endoscope reprocessing market are Advanced Sterilization Products, ARC Group of Companies Inc., CONMED Corporation, Getinge AB, Borer Chemie AG, Metrex Research LLC, and Belimed AG.